AAP
VRTX icon

Aristotle Atlantic Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Aristotle Atlantic Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.8M Sell
37,532
-859
-2% -$401K 0.78% 42
2025
Q4 		$17.4M Sell
38,391
-1,413
-4% -$609K 0.8% 41
2025
Q3 		$15.6M Sell
39,804
-5,572
-12% -$2.33M 0.45% 46
2025
Q2 		$20.2M Sell
45,376
-2,610
-5% -$1.2M 0.61% 41
2025
Q1 		$23.3M Sell
47,986
-3,265
-6% -$1.52M 0.79% 37
2024
Q4 		$20.6M Sell
51,251
-2,843
-5% -$1.32M 0.65% 37
2024
Q3 		$25.2M Buy
54,094
+1,508
+3% +$724K 0.78% 33
2024
Q2 		$24.6M Sell
52,586
-6,136
-10% -$2.66M 0.8% 32
2024
Q1 		$24.5M Buy
58,722
+31,135
+113% +$13.2M 0.8% 39
2023
Q4 		$11.2M Buy
27,587
+18,313
+197% +$6.77M 0.4% 59
2023
Q3 		$3.22M Sell
9,274
-368
-4% -$129K 0.13% 73
2023
Q2 		$3.39M Buy
9,642
+7,900
+454% +$2.66M 0.13% 75
2023
Q1 		$549K Buy
1,742
+13
+0.8% +$3.9K 0.03% 89
2022
Q4 		$499K Sell
1,729
-8
-0.5% -$2.44K 0.03% 87
2022
Q3 		$503K Buy
1,737
+258
+17% +$74.2K 0.03% 87
2022
Q2 		$417K Buy
1,479
+558
+61% +$149K 0.03% 90
2022
Q1 		$240K Buy
+921
New +$219K 0.01% 97
2021
Q3 		– Sell
-61,548
Closed -$12.4M – 102
2021
Q2 		$12.4M Buy
+61,548
New +$12.9M 0.82% 34

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Aristotle Atlantic Partners's VRTX Position: Q1 2026 in Review

Aristotle Atlantic Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q1 2026, selling an estimated $401K and leaving 37,532 shares worth $16.8M. The position accounts for 0.78% of the portfolio, ranked #42.

Aristotle Atlantic Partners first reported a position in VRTX in Q2 2021 and has held it in 18 quarters since. The position peaked at $25.2M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Aristotle Atlantic Partners held 37,532 shares of Vertex Pharmaceuticals worth $16.8M as of Q1 2026.
  • Aristotle Atlantic Partners sold 859 Vertex Pharmaceuticals shares in Q1 2026, an estimated $401K.
  • Vertex Pharmaceuticals made up 0.78% of Aristotle Atlantic Partners's portfolio in Q1 2026, its #42 holding.
  • Aristotle Atlantic Partners first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 18 quarters since.
  • Aristotle Atlantic Partners's Vertex Pharmaceuticals position peaked at $25.2M in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Aristotle Atlantic Partners's 13F filing for Q1 2026, filed 15 May 2026.